From the publishers of The New England Journal of Medicine

Save time and stay informed. Our physician-editors offer you clinical perspectives on key research and news.

Physician's First Watch

Like this article?
Get free daily
medical news from Physician's First Watch.

Antiepileptic-Class Drugs Increase Risk for Suicidality

Patients who take antiepileptics have double the risk for suicidal thoughts and behaviors (suicidality), the FDA warned on Thursday.

The agency reviewed 199 placebo-controlled studies of 11 antiepileptic drugs and found that patients taking these medications had a 0.43% risk for suicidality, as compared with those taking placebo, who had a 0.22% risk.

The agency's analysis included the following drugs:

  • carbamazepine (Carbatrol, Equetro, Tegretol)
  • felbamate (Felbatol)
  • gabapentin (Neurontin)
  • lamotrigine (Lamictal)
  • levetiracetam (Keppra)
  • oxcarbazepine (Trileptal)
  • pregabalin (Lyrica)
  • tiagabine (Gabitril)
  • topiramate (Topamax)
  • valproate (Depakote, Depakene, Depacon)
  • zonisamide (Zonegran)

The agency says that all medications in the antiepileptic class pose an increased risk for suicidality. The agency advises: "Health care providers should notify patients, their families, and caregivers ... so that patients may be closely observed for notable changes in behavior."

LINK(S):

FDA press release (Free)

New York Times story (One-time registration required)

Previous Physician's First Watch coverage of epilepsy and suicide (Free)

Published in Physician's First Watch February 1, 2008

Your Remark:

Reader Remarks are intended to encourage lively discussion of clinical topics with your peers in the medical community. Please consider this when composing your remark.

Fields marked with an * are required.

Name as you'd like it to appear:

Submitting a comment indicates you have read and agreed to the remark guidelines and declare:*

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.

 

CLEAR erases anything you've added in any part of the form. CONTINUE allows you to check your entire post (and edit it if necessary) before submitting.

To ensure that your Reader Remark is not formatted as one long paragraph, precede new paragraphs with either a blank line or an indentation.

Search

Advanced

Article Tools

Reader Remarks

Sign-In

Forgot your password?

New to Journal Watch?

E-mail Alerts

Delivered to your inbox.
Tailored to your interests. Free.

Sign Up Now!

Journal Watch Newsletters

Available in 13 specialties with convenient delivery and 10 free online CME exams.

Subscribe Now!

Copyright © 2008. Massachusetts Medical Society. All rights reserved.